Facilitating Cascade Genetic Testing Study

Genetic testing for cancer predisposition genes, including BRCA1 and BRCA2, has been available in clinical practice for over 25 years. Individuals with a BRCA1 or BRCA2 mutation have up to an 87% risk of developing breast cancer, 60% risk of ovarian cancer, and increased risks for pancreatic cancer, prostate cancer, and male breast cancer. Once an individual is identified with a BRCA mutation, genetic testing can be offered to their relatives, where efforts can be targeted at reducing their cancer risks. Testing at-risk family members of a BRCA mutation carrier is referred to as cascade testing. Relatives of a known BRCA mutation carrier have the highest known risks of developing cancer. However, less than 30% of first-degree relatives of BRCA carriers have had genetic testing, and even fewer second- and third-degree relatives. We urgently need to increase rates of cascade testing in relatives of known BRCA mutation carriers.

Digital tools have been developed to support healthcare services, including providing patient education, counselling, and decision support. Overall, digital genetics tools have been well received by patients, with high levels of usability, acceptability and satisfaction reported. These digital tools have been shown to improve patient-reported outcomes, including increasing knowledge, reducing decisional conflict, initiating active-decision making and facilitating patient-centered care.

If you are interested in participating or learning more about the Cascade Study, please contact the study team by emailing cascadestudy@wchospital.ca or calling 416-323-6400 x2749.